Introduction: Preeclampsia is a heterogeneous gestational disease characterized by maternal hypertension and proteinuria, affecting 2-7% of pregnancies. The disorder is initiated by insufficient placental development, but studies characterizing the placental disease components are lacking. Methods: Our aim was to phenotype the preeclamptic placenta using high-resolution magic angle spinning nuclear magnetic resonance spectroscopy (HR-MAS MRS). Placental samples collected after delivery from women with preeclampsia (n=19) and normotensive pregnancies (n=15) were analyzed for metabolic biomarkers including amino acids, osmolytes, and components of the energy and phospholipid metabolism. The metabolic biomarkers were correlated to clinical characteristics and inflammatory biomarkers in the maternal sera. Results: Principal component analysis showed inherent differences in placental metabolic profiles between preeclamptic and normotensive pregnancies. Significant differences in metabolic profiles were found between placentas from severe and non-severe preeclampsia, but not between preeclamptic pregnancies with fetal growth restricted versus normal weight neonates. The placental metabolites correlated with the placental stress marker sFlt-1 and triglycerides in maternal serum, suggesting variation in placental stress signaling between different placental phenotypes. Discussion: HR-MAS MRS is a sensitive method for defining the placental disease component of preeclampsia, identifying several altered metabolic pathways. Placental HR-MAS MRS analysis may improve insight into processes affected in the preeclamptic placenta, and represents a novel long-required tool for a sensitive placental phenotyping of this heterogeneous disease.
Introduction

4
Preeclampsia is a gestational disease that originates in the placenta and affects 2-7% of 5 pregnancies [1] . Preeclampsia may reflect an excessive maternal inflammatory response to 6 insufficient placentation or to pregnancy itself [2, 3] . The current hypothesis in regard to its 7 development states that the uterine spiral arteries develop insufficiently during placentation, 8 causing placental ischaemia and abnormal inflammation as the pregnancy develops [1, 4] . The 9 oxidatively stressed placenta releases increasing amounts of inflammatory and angiogenic 10 factors to the maternal circulation, eventually causing the manifestations of preeclampsia; 11 endothelial dysfunction, intravascular inflammation and activation of the hemostatic systems 12 clinically evidenced by proteinuria and hypertension [1, 4] . 13
Preeclampsia is a heterogeneous disease, and markers in the placenta identifying disease 14 subgroups are scarce [5] . Common subtypes of preeclampsia are today defined by clinical 15 characteristics such as severity of maternal features, time of diagnosis, and presence of fetal 16 growth restriction (FGR) [6, 7] . These subgroups are based on end stage maternal or fetal 17 factors, and placental histology findings and maternal serum markers overlap between groups 18 [2] . Similar end stage presentations of preeclampsia may stem from different pathologic 19 placental processes [8] . Studying the altered metabolism of the placenta in preeclampsia, and 20 how it is affected with disease severity and when combined with FGR, may give insight into 21 which processes are shared and specific for these disorders. Placental phenotyping by 22 metabolic expression may aid in identifying potential targets for treatment in the future. 23 Metabolite expression is the final level of regulation over gene and protein expression, and 24 can be measured directly in tissue samples using high resolution magic angle spinning 25 magnetic resonance spectroscopy (HR-MAS MRS) [9] . HR-MAS MRS has been used 26 successfully in investigating molecular subtypes of breast cancer for improved treatment and 27 outcome stratification [10] . HR-MAS MRS of intact placental tissue from normal or 28 preeclamptic pregnancies has not been performed previously. 29
Our aim is to identify differences in placental metabolic expression between normotensive 30 and preeclamptic pregnancies using HR-MAS MRS metabolomics. We further aim to 31 investigate whether the placental metabolites correlate to maternal serum measurements of 32 placental stress and inflammatory markers. We hypothesize that placental metabolic profiling 33 provides a sensitive method for detailed identification of the placental component of 34 measured by accredited methods at the Department of Clinical Chemistry, St. Olavs Hospital, 84
Trondheim, Norway. 85
HR-MAS MRS placental analyses
86
The placental biopsies were analyzed in random order, blinded to pregnancy outcome. 87
Samples were prepared on a metal plate cooled in liquid nitrogen in order to minimize the 88 effect of tissue degradation, as described in [15, 16] . Biopsies (7.5 ± 1.4 mg) were cut to fit 89 30µL disposable inserts (Bruker Biospin Corp, USA) filled with 3µL D 2 O containing 25mM 90 formate for shimming. Spin-echo spectra were acquired on a Bruker Avance DRX600 91 spectrometer with a 1 H/ 13 C MAS probe with gradient (Bruker Biospin GmbH, Germany) 92 using the following parameters: 5KHz spin rate, 5°C probe temperature, cpmgpr1d pulse 93 sequence (Bruker Biospin) with 78ms total echo time, spectral width of 20 ppm and 256 94 scans. Two samples were additionally analyzed by 13 C-1 H spectroscopy (HSQC, HMBC) for 95 aid in metabolite identification. 96
Data analysis
97
Spectra were Fourier transformed into 65.5k points following 0.3 Hz line broadening, and 98 automatically phased and baseline corrected (Topspin 3.1, Bruker Biospin). The spectra were 99 restricted to the region 0.5 to 4.7 ppm, peak aligned using iCoshift to correct for slight 100 variations in peak positions [17] , and divided by the total area under the spectrum curve to 101 account for variation in sample weight. Eight preeclamptic women had both FGR neonates and severe preeclampsia features, and 116 these were included both in the FGR group and the severe preeclampsia group in subgroup 117
analyses. The performance of the PLS-DA models was evaluated by five-fold cross-validation 118 which was repeated twenty times. The number of latent variables was chosen as the number 119 giving the highest accuracy of classification. Sensitivity, specificity and classification 120 accuracy were reported as averages from the validation set for each model. To evaluate the 121 validity of the regression and classification results, 1000 permutation tests were performed 122 with models considered valid at p≤0.05. In permutation testing, classes or dependent values 123 are shuffled and models built on the random data [22] . The classification results from the true 124 model should then be outside the 95% confidence limit for the permuted models to be 125 considered valid. 126
Univariate statistical analyses were performed in SPSS v. 20 (SPSS, Chicago, IL). Clinical 127 characteristics were compared between disease subgroups using the one-way ANOVA with 128
Tukey post-hoc test for groupwise normally distributed data (GA, birth weight) or the Kruskal 129
Wallis test with post-hoc pairwise Mann-Whitney U tests for nonparametric data (maternal 130 age, blood pressure, body mass index (BMI), placental weight, parity), or Fishers exact test7 for categorical variables. Metabolite levels and serum measurements were compared using the 132
Mann-Whitney U test. False discovery rate correction for multiple testing (Benjamini-133
Hochberg) was applied [23] . To adjust for confounding effects of GA, linear regression 134 models with log-transformed metabolites as dependent variable and preeclampsia and GA as 135 independent variables were generated. Interaction terms between preeclampsia and covariates 136 were included in the models if significant, otherwise excluded. Standardized residuals were 137 assessed with the Kolmogorov Smirnov test. Quantitative metabolite set enrichment analysis 138 (MSEA) was performed for inferring the metabolic pathways associated with disease [24] . 139
Results
140
Clinical characteristics
141
The clinical characteristics of the study participants are described in Tab. 1. A total of 34 142 pregnant women were included in the study (preeclampsia; n=19 and normotensive; n=15). 143
Birth weight and GA were lower in women with preeclampsia than in normotensive 144 pregnancies, and preeclamptic women were more likely to be primiparous. Maternal serum 145 levels of creatinine, uric acid and sFlt-1 were significantly higher before delivery in women 146
with preeclampsia compared to normotensive women (Tab. 2). 147
HR-MAS analyses
148
In total 25 metabolites were identified in the HR-MAS MRS analysis of placental biopsies 149 (Supplementary Tab. S.3). The metabolite levels are shown in Tab. 2, grouped by metabolic 150 pathway [25] . Median spectra from placental biopsies from normotensive and preeclamptic 151 pregnancies are shown in Fig. 1 . 152
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The results from PCA are shown in Fig. 2 . The score plots show the between-samples 154 variation and are colored by ellipses of 95% confidence intervals for preeclampsia subgroups 155 defined by presence or absence of preeclampsia ( Fig. 2A) , severe or non-severe preeclampsia 156 (Fig. 2B) or preeclampsia with or without FGR (Fig. 2C) . Superimposed preeclampsia 157 appeared in the overlapping region in the score plot between preeclampsia and normal 158 pregnancy ( Fig. 2A) . Normotensive pregnancies were clearly different from preeclamptic 159 pregnancies in placental metabolic expression profile. The preeclamptic pregnancies showed a 160 more heterogeneous metabolic expression than the more unified group of normotensive 161 pregnancies ( Fig. 2A) . Placentas from preeclamptic pregnancies showed enrichment of 162 phospholipid biosynthesis and depletions in bile acid biosynthesis, taurine metabolism, 163 ammonia and urea cycles and protein biosynthesis, compared to placentas from normotensive 164 pregnancies (Supplementary Tab. S.4). No effect of fetal sex, maternal age or body mass 165 index on the placental metabolic profiles was found using PLS-DA. 166
The preeclampsia subgroups defined by severe preeclampsia or FGR had overlapping 167 metabolic expressions ( Fig. 2B and C) . The severe preeclampsia placental profiles were more 168 similar to the normotensive profiles than preeclampsia without severe features (Fig. 2B) . In 169 contrast, placental metabolic profiles of preeclampsia with FGR were more separated from 170 normotensive profiles than preeclampsia without FGR (Fig. 2C) . The loading plot (Fig. 2D)  171 identified the metabolites contributing to the sample distributions. The first principal 172 component (PC1) showed an increase in aspartate, phosphocholine and 173 glycerophosphocholine and decrease in glutamate, taurine, ascorbate and glutamine 174 corresponding to a preeclamptic phenotype. The second PC (PC2) showed variation not 175 related to group separation: relative to samples with low scores on PC2, samples with high 176 scores on PC2 had increased phosphocholine, glycerophosphocholine, myo-inositol and 177 threonine, and lower lactate, glycine and glycerol. Several metabolic pathways were affected in preeclampsia; notably the taurine, glutamate and 223 phospholipid metabolism. Taurine is an essential nutrient in fetal metabolism, as the fetus and 224 placenta lack the enzyme for taurine synthesis [30] . Reduced activity of a placental taurine 225 transporter has been found in preeclampsia and FGR [31, 32] . Reduced taurine in the placenta 226 may impair syncytiotrophoblast cell renewal and lead to decreased nutrient transfer to the 227 fetus [32] . In our study, taurine levels were similar in placentas from preeclampsia with or 228 without FGR, suggesting that taurine depletion is not specific for FGR. Glutamine and 229 glutamate are crucial to the fetal carbon and nitrogen metabolism as precursors to protein, 230 purine and pyrimidine synthesis [33] . Glutamate is also a precursor to glutathione, an 231 important antioxidant, and has been shown to be lower in medium of placental explants from 232 hypoxic normal tissue and preeclamptic tissue [26] . Consistent with this finding, placental 233 ascorbate was significantly lower in preeclamptic placentas. Intracellular ascorbate protects 234 endothelial cells from apoptosis induced by hypoxia followed by reoxygenation, and may be 235 depleted as a response to hypoxia [34] . 236
Two possible reasons for increased glycerophosphocholine in preeclampsia are suggested. 237
First, the increase may be due to excessive cell death in preeclamptic placentas [35, 36] . This 238 conforms to our findings of increased glycerophosphocholine especially in those pregnancies 239 with increased maternal serum sFlt-1. Phosphatidylcholine catabolism releases 240 glycerophosphocholine and arachidonic acid by the phospholipase PLA 2 , possibly playing a 241 role in increased inflammation, a central process in the preeclamptic placenta. PLA 2 activity is 242 increased in preeclamptic placental tissue [37] . Second, the increase may stem from placental 243 cell membrane catabolism for regeneration of choline methyl groups due to folate deficiency 244
[38]. In our study, glycerophosphocholine was no longer significantly different between 245 groups after adjustment for gestational age, as the metabolite decreases towards term in the 246 preeclampsia group. The metabolite may still play a role in early onset disease. An MR 247 imaging study of in utero placentas found increased placental phosphodiester components 248 including glycerophosphocholine in early onset preeclampsia compared to gestational age 249 matched controls [39] , supporting that the increase is disease-related and not only dependent 250 on gestational age. However, our data cannot separate these two effects. Choline levels were 251 in this study similar in preeclamptic and normotensive placentas, indicating a compensatory 252 mechanism. Another component of phospholipid biosynthesis, ethanolamine, was decreased 253 in the preeclamptic placenta. Ethanolamine kinase deficient mice have low birth weight 254 offspring and increased placental thrombosis and apoptosis, indicating an important role of 255 ethanolamine in placental and fetal development [40] . An earlier metabolomics study using 256 mass spectrometry of placental extracts found increased choline, succinate and 257 glycerophosphocholine species in placentas from preeclamptic pregnancies [28], the two 258 former of which we found no difference. However, many metabolites measured with MS are 259 not observed in MRS spectra. 260
The correlation of placental metabolic profiles to maternal serum sFlt-1 and triglycerides 261
suggests that different placental phenotypes may be recognized by targeted measurements of 262 maternal markers. Placental sampling must be done after delivery, but importantly, increased 263 understanding of underlying placental disease components will enable a more targeted search 264 for disease markers that more accurately reflect the diversity of the placental disease. 265
Identification of a placental phenotype correlating to maternal serum markers is an important 266 step in this direction. Novel markers reflecting the placental disease more directly will still 267 need to be identified. 268
Limitations of our study include the variation in GA between preeclamptic and normotensive 269 pregnancies. Differences were accounted for using linear regression, but variation due to GA 270 cannot easily be overcome in placenta research due to the nature of the preeclampsia 271 diagnosis. Additionally, only one sample per placenta was analyzed, thus, intra-individual 272 variability was not assessed. However, previous metabolomic analyses of the placenta found 273 no or few spatial differences in metabolites [28, 41] . Finally, the time passed between CS and 274 tissue freezing was longer than recommended for metabolomics studies, and therefore the 275 metabolic profiles may not directly reflect the in vivo situation [41, 42] . Strengths of our 276 study are the whole tissue profiling without need for extraction and derivatization, and the 277 sensitivity as reflected by metabolite correlation to the placental derived stress factor sFlt-1 in 278 maternal serum. All deliveries were by CS precluding any labor-induced variation. Sensitive 279 placental profiling as shown here is missing from preeclampsia research. 280
Metabolomics represents the closest measure to the phenotype, and this is reflected in the 281 highly significant differences between placentas from normotensive and preeclamptic 282 pregnancies. In this study we investigated pathways affected by preeclampsia, and found 283 metabolic profiles specific for severe preeclampsia and correlating to increased maternal 284 serum markers. An interesting direction of further research will be to metabolically classify 285 the placental component of preeclampsia in larger cohorts, and identify unique factors that 286 may benefit from separate treatments as has been done previously using gene expression 287 analysis [43] . We present the HR-MAS MRS method as an excellent novel tool for placental 288 disease phenotyping in pregnancy research possibly leading to future improved screening, 289 prediction and follow-up of pregnant women at risk for preeclampsia. 290 b Maternal weight for BMI calculation was measured at the first prenatal care visit, before week 12 of pregnancy. Weight information was missing for one woman with severe PE and FGR, and one normotensive woman. c Pregestational CVD diagnoses included: pregestational hypertension, cardiomyopathies, congenital cardiac defects. d Birth weight <5 th percentile according to fetal weight reference curves [11] was used as a proxy for one of the FGR diagnoses. * p<0.05 compared to normotensive. ** p<0.001 compared to normotensive. *** p<0.05 compared to preeclampsia. Abbreviations: BMI; body mass index; BP; blood pressure; CVD, cardiovascular disease; GA; gestational age; FGR, fetal growth restriction; IQR; interquartile range; NA, not applicable; md; median; mn, mean; n, number; PE, preeclampsia; SD, standard deviation 005 Metabolite levels are in arbitrary units relative to total spectral intensity. Metabolites and serum values were compared between preeclamptic and normotensive groups using the MannWhitney U test. Metabolites grouped by metabolic pathways described in the small molecule pathway database [21] . The metabolites may be involved in several pathways. Abbreviations: GA, gestational age; HDL, high density lipoprotein; hsCRP, high sensitivity C-reactive protein; IQR, interquartile range; sFlt-1, soluble Fms-like tyrosine kinase receptor 1; PE, preeclampsia. a Corrected for multiple comparisons using the Benjamini-Hochberg false discovery rate. b Corrected for gestational age. Linear regression models were made with log transformed metabolite levels as dependent variable and gestational age as independent variable. The metabolite is then evaluated at the average values GA=245 days. c One placenta-serum pair was excluded due to missing blood sample. Placental metabolic profiles were compared between groups using partial least squares discriminant analysis (PLS-DA), and the discriminatory ability assessed with 5-fold cross validation. a p value from 1000 permutation tests. Abbreviations: 3-HB, 3-hydroxybutyrate; Ala, alanine; Asc, ascorbate; Asp, aspartate; Cho, choline; EtAm, ethanolamine; FGR, fetal growth restriction; Gln, glutamine; Glu, glutamate; GPC, glycerophosphocholine; Gly, glycine; Lys, lysine; LVs, latent variables; Myo, myo-inositol; Tau, taurine; PCho, phosphocholine; PE, preeclampsia; PLS-DA, partial least squares discriminant analysis; rel, relative; sens, sensitivity; sFlt-1, soluble fms-like tyrosine kinase receptor 1; spec, specificity; Suc, succinate; Val, valine. Metabolite set enrichment analysis results (Performed on Metaboanalyst online, www.metaboanalyst.ca [1] ). a Total number of compounds (metabolites) in the pathway b Number of measured metabolites found in pathway c Q-statistic describing the correlation between compound concentration profiles and phenotype labels d Expected Q statistic given no correlation between compounds and phenotype labels e P value for the probability of obtaining the Q statistic f P values corrected for multiple correction using false discovery rates .2) 0.687 0.818 Metabolites were compared between groups using the Mann-Whitney U test. Metabolites grouped by metabolic pathways described in the small molecule pathway database [2] . The metabolites may be involved in several pathways. Metabolite levels are in arbitrary units relative to total spectral intensity. Abbreviations: FDR, false discovery rate; IQR, interquartile range; PE, preeclampsia. a Corrected for multiple comparisons using the Benjamini-Hochberg false discovery rate. * Significantly different between severe and non-severe preeclampsia after correction for multiple testing.
Table S.6
Comparison between metabolite levels in placentas from women with preeclamptic and normotensive pregnancies, with adjustments for gestational age. comparisons) is given. For the gestational age adjusted p values, linear regression models were made with log transformed metabolite levels as dependent variable and gestational age as independent variable. The metabolite is then evaluated at the average values GA=245 days. Abbreviations: 3HB, three-hydroxybutyrate; GA, gestational age; PE, preeclampsia. a Adjusted for multiple comparisons using the Benjamini-Hochberg false discovery rate for all tested metabolites. * Significantly different between normotensive and preeclamptic placentas after correction for difference in gestational age. Abbreviations: FGR, fetal growth restriction; non-sev., non-severe; PE, preeclampsia, ROC, receiver-operator characteristic.
